Syndicate content

Archive - Feb 7, 2019

Date

Unexpected Finding in Study of Activated Platelets in Heart Disease May Enable Novel Approach to Early Detection & Destruction of Difficult-to-Treat Cancers

An unexpected finding in pre-clinical platelet studies by Baker Institute researchers in Melbourne, Australia, could provide a novel approach to targeting and destroying difficult-to-treat cancer cells, providing new therapeutic options for a range of cancers. This latest finding, published in the journal Theranostics, was discovered while studying activated platelets in the setting of heart disease and may now prove useful for delivering targeted treatment to cancer cells without major side effects. Early detection of cancer is crucial for successful therapy. However, some cancer types do not have specific cancer surface markers that can be used to detect them and even the same cancer type can exhibit different properties in different patients. Professor Karlheinz Peter, Deputy Director, Basic and Translational Science at the Baker Heart and Diabetes Institute has been working for many years with platelets, which are small blood cells in the circulation that mainly promote blood clotting (for example, platelets are the main perpetrator of a heart attack) and prevent us from bleeding when we are injured. In his recent experiments, he observed that platelets and more specifically, "activated platelets" accumulate in the area surrounding a wide range at tumor types. Based on this observation, Professor Peter's team has now developed a new imaging and platelet targeting chemotherapy agent for the early detection and treatment of cancers. "We have shown that we can image activated platelets to detect tumors with clinically available imaging technologies such as ultrasound and PET/CT," he said. "This unique approach holds great promise both for the diagnosis and therapy of a broad range of tumors.

At PMWC 2019, Yinuoke CEO Argues for Massive Effect of Drugs Targeting Late-Stage Tumor-Induced Immune Disorder (TID), 30% of Cancer Deaths Could Be Prevented, Dr. Lingbing Zhang Claims; Two Prominent Oncologists Endorse Yinuoke’s Novel Approach

Immunotherapy was a major theme of the Precision Medicine World Conference (PMWC 2019) at Santa Clara, California, this January 21-23 and on the second day of the three-day main conference, Lingbing Zhang, PhD, Founder & CEO of Yinuoke Limited, a clinical-stage biotech company, gave an especially interesting presentation in which he described his company’s efforts to combat problems typically encountered in the late stages of cancer, namely tumor-induced immune disorder (TID) and cachexia, termed “The Last Illness” in a Nature article (https://www.nature.com/news/cachexia-the-last-illness-1.18961). Dr. Zhang’s presentation focused on three major points: TID can bring massive damage to the host; TID impacts efficacy of immune checkpoint inhibitors; and a new direction to develop cancer treatment can pursued by targeting TID. Dr. Zhang founded Yinuoke, Ltd., in 2016 with the specific purpose of discovering and developing innovative cancer treatments by targeting TID. Dr. Zhang believes that Yinuoke is the first company to develop new cancer treatments by targeting TID. The new term “tumor-induced immune disorder (TID)” was first proposed by Yinuoke, because the company believes this term more accurately describes the immune status of cancer patients at the late stage of disease. If you look at the blood of patients with late -stage cancer, you will always see severely imbalanced immune cell populations, such as high neutrophils and low lymphocytes, Dr. Zhang asserts, and you will see multiple dramatically elevated cytokines.